Advances in treatment of hyperkalemia in chronic kidney disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Hyperkalemia is a frequent electrolyte disorder associated with life-threatening cardiac arrhythmias and sudden death. Patients prone to hyperkalemia have chronic kidney disease (CKD) either alone or in conjunction with diabetes or heart failure (HF). Although agents inhibiting the renin-angiotensin-aldosterone-system (RAAS) are currently the first-line treatments toward cardio- and nephroprotection, their administration often leads to potassium elevation in such patients and results in high rates of treatment discontinuation. AREAS COVERED: This article provides an overview of factors interfering with potassium homeostasis and discusses emerging potassium-lowering therapies for long-term management of hyperkalemia. EXPERT OPINION: In recent randomized clinical studies, two new oral potassium-exchanging compounds, patiromer and sodium zirconium cyclosilicate, were shown to effectively normalize elevated serum potassium and chronically maintain potassium homeostasis in hyperkalemic patients treated with RAAS blockers. Both agents exhibit good tolerability and were not associated with serious adverse effects. Although additional research is required, these drugs are promising for lowering the risk of incident hyperkalemia associated with RAAS blockade use in people with diabetes or HF who have CKD. They also provide the opportunity to test whether patients who could not previously receive RAAS blockade may benefit from their cardio- and renoprotective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“Importantly, clinical studies have shown that administration of a lower dose of spironolactone, eplerenone, and ramipril is associated with reduced risk of potassium rise while retaining the cardio- and renoprotective actions of RAAS blockade [54-56].”
BackgroundCardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Alonso, A., Lau, J., Jaber, B. L., Weintraub, A., & Sarnak, M. J. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.09.009 · Cited by 345
Hyperkalemia and hyporeninemic hypoaldosteronism
DeFronzo, R. A. (1980) · Kidney International · doi:10.1038/ki.1980.14 · Cited by 323 · cited 2×
“In the subset of patients with hyporeninemic hypoaldosteronism, administration of aldosterone (in the form of oral fludrocortisone acetate) is partially effective to restore potassium balance [17].”
BackgroundPrediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164 · cited 5×
“This hyperkalemia risk is enhanced when CKD patients have concomitant diabetes or heart failure (HF) [3,4].”
BackgroundInfluentialSelf-citationAgarwal, R., Sinha, A. D., Pappas, M. K., & Ammous, F. (2014) · American Journal of Nephrology · doi:10.1159/000358603 · Cited by 99
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationCollins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 403
Sarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Self-citationHyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2245756 · Cited by 11
Self-citation
Metadata
- Authors
- Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2015-08-25
- Volume
- 16
- Issue
- 14
- Pages
- 2205-2215
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1831374838
- Cited by
- 36
- References
- 10
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in treatment of hyperkalemia in chronic kidney disease. https://app.cochat.ai/papers/10.1517/14656566.2015.1083977
- The paper
- Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L. (2015). Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1083977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.